Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study

INTRODUCTION: The fixed-ratio combination of insulin glargine (iGlar) plus lixisenatide (iGlarLixi) has proven efficacious in clinical trials; however, there is limited evidence of its benefits in a variety of real-world patients with type 2 diabetes mellitus (T2DM) who present in routine clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Ankita, Samnaliev, Mihail, Ken-Opurum, Jennifer, Srinivas, Sistla S. S., Mehta, Aashay M., Dex, Terry, Charland, Scott, Revel, Andrew, Preblick, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299979/
https://www.ncbi.nlm.nih.gov/pubmed/37289358
http://dx.doi.org/10.1007/s13300-023-01419-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299979/
https://www.ncbi.nlm.nih.gov/pubmed/37289358
http://dx.doi.org/10.1007/s13300-023-01419-z

Ejemplares similares